Crispr Therapeutics AG, which is preparing nine gene-edited projects for clinical testing, has raised $91 million with an initial public offering (IPO) of shares on the Nasdaq market in the US and a private placement in Europe. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals
